DV
Dividend Vision

JUNS — Jupiter Neurosciences, Inc. Common Stock

Jupiter Neurosciences, Inc. Common Stock (JUNS)

Total return is -98.7% over the past 1.7 years, 129.9 points behind SPY at 31.2%. Its deepest 1-year drawdown was 96.6%.

Jupiter Neurosciences is a clinical-stage pharmaceutical company developing therapeutics for central nervous system disorders and rare diseases, with four drug candidates in Phase II trials targeting conditions including Parkinson's disease, Alzheimer's disease, and rare genetic disorders, alongside a nutritional supplements business under the Nugevia brand. The company does not currently distribute dividends. This security may appeal to investors with a high risk tolerance seeking exposure to early-stage drug development, as the company's value depends primarily on the success of its clinical trials and future commercialization efforts.

JUNS key facts

Asset type
Stock
Asset class
Equity
Inception date
12/03/2024
Last close
$5.24
Market cap
$8,183,631
Average volume
106000.0
Payout ratio
0.0
Forward P/E
6.9686
EPS
$-0.26